Nagasaki University

Public University Corporation Yokohama City University

Nagoya City University

Aritaka Nagadoi

Hiroshi Ueda

Yoshio Goshima

Naoki Miyata

Naoya Yamashita

Takayoshi Suzuki

Ryuta Hiraishi

Yoshifumi Nishimura

Yuuka Hirao

The present invention identifies a compound which binds to the PAH1 domain of mSin3B that specifically binds to neural restrictive silencer factor NRSF, and uses the compound as a prophylactic and/or a therapeutic for diseases associated with abnormal expression of neural restrictive silencer factor NRSF/REST or abnormal expression of genes targeted by NRSF/REST, such as Huntington's disease, medulloblastoma and neuropathic pain. The present invention provides a pharmaceutical composition comprising a substance capable of binding to the PAH1 domain of mSin3B, e.g., a compound represented by the following formula (1), a pharmacologically acceptable salt thereof, or a pharmacologically acceptable ester thereof: wherein n represents 0 or 1; R, R, R, Rand Reach independently represent a hydrogen atom, a hydrocarbon group or a functional group; Y represents a single bond, a carbonyl group, &#x2014;CONH&#x2014;, &#x2014;NHCO&#x2014; or a sulfonyl group; and Z represents a nitrogen-containing heterocyclic group which may have a substituent, an amino group which may have a hydrocarbon group or an aromatic hydrocarbon group, or a nitrogen and oxygen-containing heterocyclic group which may have a substituent.

Use of compound binding to mSin3B that specifically binds to neuron restrictive silencer factor (NRSF)

Growing community of inventors

Yokohama, Japan

Aritaka Nagadoi